Suède - suédois - Läkemedelsverket (Medical Products Agency)

baxter medical ab - alanin; arginin; asparaginsyra; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; leucin; lysinacetat; metionin; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - alanin 16 g aktiv substans; treonin 5,53 g aktiv substans; serin 4,38 g aktiv substans; prolin 6,6 g aktiv substans; fenylalanin 7,68 g aktiv substans; tyrosin 0,28 g aktiv substans; valin 7,08 g aktiv substans; lysinacetat 12,2 g aktiv substans; tryptofan 1,85 g aktiv substans; arginin 10,9 g aktiv substans; asparaginsyra 3,2 g aktiv substans; glutaminsyra 5,53 g aktiv substans; glycin 7,68 g aktiv substans; histidin 6,6 g aktiv substans; isoleucin 5,53 g aktiv substans; leucin 7,68 g aktiv substans; metionin 5,53 g aktiv substans

Suède - suédois - Läkemedelsverket (Medical Products Agency)

baxter medical ab - alanin; arginin; asparaginsyra; fenylalanin; glutaminsyra; glycin; histidin; isoleucin; leucin; lysinacetat; metionin; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - arginin 14,7 g aktiv substans; asparaginsyra 4,34 g aktiv substans; alanin 21,7 g aktiv substans; lysinacetat 16,7 g aktiv substans; glutaminsyra 7,49 g aktiv substans; glycin 10,4 g aktiv substans; histidin 8,94 g aktiv substans; isoleucin 7,49 g aktiv substans; leucin 10,4 g aktiv substans; metionin 7,49 g aktiv substans; fenylalanin 10,4 g aktiv substans; prolin 8,94 g aktiv substans; serin 5,92 g aktiv substans; treonin 7,49 g aktiv substans; tryptofan 2,5 g aktiv substans; tyrosin 0,39 g aktiv substans; valin 9,6 g aktiv substans

Union européenne - suédois - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Union européenne - suédois - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Suède - suédois - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - betametasondipropionat; kalcipotriolmonohydrat - gel - 50 mikrogram/g + 0,5 mg/g - betametasondipropionat 0,643 mg aktiv substans; kalcipotriolmonohydrat 52 mikrog aktiv substans; butylhydroxitoluen hjälpämne

Suède - suédois - Läkemedelsverket (Medical Products Agency)

orifarm generics a/s - betametasondipropionat; kalcipotriolmonohydrat - gel - 50 mikrogram/g + 0,5 mg/g - butylhydroxitoluen hjälpämne; betametasondipropionat 0,643 mg aktiv substans; kalcipotriolmonohydrat 52 mikrog aktiv substans

Suède - suédois - Läkemedelsverket (Medical Products Agency)

abbvie ab - karbidopa (monohydrat); levodopa - intestinal gel - 20 mg/ml + 5 mg/ml - levodopa 20 mg aktiv substans; karbidopa (monohydrat) 5 mg aktiv substans - levodopa och dekarboxylashämmare

Suède - suédois - Läkemedelsverket (Medical Products Agency)

sensidose ab - karbidopa (monohydrat); levodopa - dispergerbara tabletter för dosdispenser - 5 mg/1,25 mg - karbidopa (monohydrat) 1,35 mg aktiv substans; levodopa 5 mg aktiv substans - levodopa och dekarboxylashämmare

Suède - suédois - Läkemedelsverket (Medical Products Agency)

sandoz a/s - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - betametasondipropionat 0,643 mg aktiv substans; kalcipotriolmonohydrat 0,052 mg aktiv substans

Suède - suédois - Läkemedelsverket (Medical Products Agency)

orifarm ab - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - betametasondipropionat 0,643 mg aktiv substans; kalcipotriolmonohydrat 0,052 mg aktiv substans